Daewoong Pharmaceutical Accelerates Entry into US Botulinum Toxin Treatment Market

[Asia Economy Reporter Cho Hyun-ui] Daewoong Pharmaceutical announced on the 3rd that its botulinum toxin treatment business partner Ion Biopharma has received FDA approval for Phase 2 clinical trials for the indication of 'cervical dystonia.' The clinical trial is scheduled to begin in the first half of next year.

Ion Biopharma is Daewoong Pharmaceutical's exclusive partner for advanced countries' botulinum toxin treatment business, holding exclusive rights related to commercialization such as approval, import, and sales of Daewoong Pharmaceutical's products for therapeutic purposes in the United States, Europe, Canada, and other regions.

Cervical dystonia, which received clinical approval this time, is a neurological disorder characterized by spasms, contractions, or abnormal positioning of neck muscles. It is a chronic disease that cannot be completely cured, and botulinum toxin administration is the standard treatment.

Ion Biopharma plans to acquire additional therapeutic indications beyond cervical dystonia. Among the indications currently under research, there are some that are being developed for the first time worldwide.

Daewoong Pharmaceutical has decided to invest $25 million in convertible bonds in Ion Biopharma to strengthen the partnership based on this clinical approval.

A Daewoong Pharmaceutical official said, "Ion Biopharma is expected to strengthen the huge advanced country treatment market business by completing clinical development early with stable funding secured through Daewoong Pharmaceutical's investment."

Jeon Seung-ho, CEO of Daewoong Pharmaceutical, said, "Entering the advanced countries' toxin treatment market is a representative future growth business that Daewoong Pharmaceutical has long prepared together with its partner," adding, "We will do our best until the end for the global success of K-pharmaceutical bio."

This content was produced with the assistance of AI translation services.